Analysts at JPMorgan Chase & Co. started coverage on shares of Hemab Therapeutics (NASDAQ:COAG – Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an “overweight” rating and a $70.00 price target on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 133.80% from the company’s current price.
COAG has been the topic of a number of other research reports. Rodman & Renshaw started coverage on Hemab Therapeutics in a research report on Monday. They issued a “buy” rating and a $56.00 price target on the stock. HC Wainwright raised their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Jefferies Financial Group boosted their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Finally, Wedbush upped their price target on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.71.
Read Our Latest Report on COAG
Hemab Therapeutics Price Performance
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, analysts predict that Hemab Therapeutics will post -3.09 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp acquired a new position in Hemab Therapeutics during the second quarter worth about $2,825,000. Opaleye Management Inc. bought a new position in shares of Hemab Therapeutics in the second quarter worth about $1,750,000. The Manufacturers Life Insurance Company bought a new position in shares of Hemab Therapeutics in the second quarter worth about $688,000. Squarepoint Ops LLC acquired a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at approximately $230,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at approximately $19,226,000.
Hemab Therapeutics Company Profile
Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.
Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.
Read More
- Five stocks we like better than Hemab Therapeutics
- Mortgage Rates Squeeze FHA Buyers: 3 Housing Stocks to Watch
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
